Article Details

Pfizer, Erasca Partner to Study Three-Drug Combo in BRAF V600E-Mutated Metastatic Colon Cancer

Retrieved on: 2021-09-08 15:33:45

Tags for this article:

Click the tags to see associated articles and topics

Pfizer, Erasca Partner to Study Three-Drug Combo in BRAF V600E-Mutated Metastatic Colon Cancer. View article details on hiswai:

Excerpt

NEW YORK – Erasca on Wednesday said it has partnered with Pfizer on a trial evaluating its ERK1/2 inhibitor ERAS-007 with Pfizer's encorafenib ...

Article found on: www.precisiononcologynews.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up